All In Biotech

Drug Trial Radar · NCT07755150

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study Assessing the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes Mellitus.

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 272 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

272

Planned (sponsor's estimate)

Start

Aug 30, 2026

Primary completion

Oct 20, 2027

Study completion Oct 20, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study aims to assess the efficacy, safety, and PK characteristics of DA-302168S tablets in Chinese T2DM participants, and to provide dose-selection evidence for the Phase III confirmatory trial.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • DA-302168SDrug

    A small molecule GLP-1R agonist tablet, orally administration, once daily,16weeks.

  • Placebo of DA-302168SDrug

    Matching placebo tablet will be provided

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in HbA1cTime frame: From baseline (week 1) to week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.